| Similar Articles |
|---|
 |
The Motley Fool
February 14, 2005
Brian Gorman |
GM Pulls Out of Walgreen The pharmacy's mail-order policy spurs the automaker's cost-containment decision.   |
The Motley Fool
February 16, 2005
Brian Gorman |
Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies? |
The Motley Fool
November 2, 2005
Brian Gorman |
Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note. |
The Motley Fool
January 3, 2012
Shubh Datta |
Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts. |
CFO
March 1, 2012
David McCann |
Companies May Win This Drug War The conflict between Express Scripts and Walgreen just might lead to lower drug-benefit costs for companies. |
The Motley Fool
December 6, 2007
Selena Maranjian |
Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall. |
The Motley Fool
July 29, 2004
Brian Gorman |
Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look. |
The Motley Fool
July 27, 2004
Brian Gorman |
Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans. |
The Motley Fool
October 8, 2011
Shubh Datta |
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide. |
The Motley Fool
March 4, 2005
Tom Taulli |
In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors. |
The Motley Fool
April 19, 2011
Bryan White |
Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies. |
The Motley Fool
February 15, 2006
Stephen D. Simpson |
Good Marks for Caremark The pharmacy benefits management company should have even more positive operating leverage left in the tank. Investors, take note. |
The Motley Fool
November 4, 2009
Brian Orelli |
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. |
The Motley Fool
July 6, 2007
Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers. |
The Motley Fool
June 30, 2011
David Williamson |
Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split. |
The Motley Fool
January 7, 2010
Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition. |
The Motley Fool
November 9, 2005
Brian Gorman |
Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company. |
The Motley Fool
June 12, 2006
Brian Gorman |
Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note. |
Managed Care
October 2005 |
Health Plans Pay Less When PBM Owns Mail-Order Pharmacy The ongoing debate on whether health plans pay more for drugs when using a mail-order pharmacy owned by a pharmacy benefits manager (PBM) or when the mail-order pharmacy is not owned by a PBM may be closer to resolution. |
The Motley Fool
June 10, 2010
Claire Stephanic |
CVS Caremark vs. Walgreen The two go head-to-head in competition for pharmacy customers. |
The Motley Fool
July 6, 2007
Mike Cianciolo |
Walgreen: The New Deal Maker Walgreen announces its latest acquisition as it tries to keep pace with the competition. Investors, take note. |
The Motley Fool
December 29, 2005
Brian Gorman |
PBMs at a Crossroads One prediction that's sure to come true next year -- drug prices will rise. Pharmacy benefit management (PBM) companies will respond. But the year ahead promises to be trickier for investors seeking to profit from PBMs. |
The Motley Fool
October 29, 2009
Brian Orelli |
Expressing Itself Nicely A nice quarter for Express Scripts. |
Managed Care
October 2003 |
Medco Health Solutions tops consumer survey The 2003 WilsonRx Survey reports that patients have identified Medco Health Solutions as the top pharmacy benefit manager for the third year in a row. |
The Motley Fool
February 28, 2005
Brian Gorman |
Medco Covers Its Bases Medco's purchase of Accredo is a nod to future growth in biotech drug spending. |
The Motley Fool
November 3, 2010
Brian Orelli |
A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it. |
The Motley Fool
June 29, 2006
Ryan Fuhrmann |
Walgreen's Prescription for Growth The drugstore chain continues to roll, even if it is a bit pricey. Great companies rarely trade at bargain-basement levels. But if savvy investors keep a watchful eye, they may find an opportunity to pick up some shares at a fairer price. |
The Motley Fool
September 29, 2010
Andrew Bond |
Walgreen Surprises the Experts Walgreen posts a great quarter as competition falters. |
Managed Care
September 2005
Martin Sipkoff |
Mail Order Pharmacy Saves Money, Says PCMA, but at What Cost? The savings to consumers and employers are apparent, but are health plans left holding the bag in mail-order pharmacy? |
The Motley Fool
July 25, 2011
Brian Orelli |
Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion. |
The Motley Fool
June 24, 2011
Shubh Datta |
A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term. |
The Motley Fool
April 30, 2008
Brian Orelli |
Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs. |
The Motley Fool
August 15, 2005
Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. |
The Motley Fool
November 11, 2011
Dan Caplinger |
Has Walgreen Become the Perfect Stock? Given that drug retail is a low-margin business, it's improbable that Walgreen will ever reach true perfection. But with some help, improving growth numbers is a goal that could be within reach. |
The Motley Fool
September 27, 2004
Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. |
The Motley Fool
March 27, 2006
Jeremy MacNealy |
Just What the Doctor Ordered Walgreen continues to shine as pharmacy sales remain healthy. Investors, take note. |
Managed Care
January 2001 |
Express Scripts' Formulary Rulings To Go Online The public will have a chance to see what until now has been, mostly, understood only by managed care insiders: how a prescription drug winds up on a formulary... |
The Motley Fool
March 23, 2011
Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount. |
The Motley Fool
February 25, 2009
Brian Orelli |
The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers. |
The Motley Fool
January 3, 2005
Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool
June 22, 2006
Stephen D. Simpson |
Rite Aid: Not Quite Rad, but Not All Bad Better results are possible, but there might be better ideas for investors. |
BusinessWeek
May 9, 2005
Weintraub & Barrett |
BW 50: Can Caremark's Health Hold Up? Caremark Rx Inc. faces a growing set of legal and market challenges, but Its drug-benefit business is soaring, and its CEO remains upbeat about the future. |
Managed Care
May 2002 |
Study: Mail Order Pharmacy Keeps Growing in Popularity The tech-savvy may denigrate it as "snail mail," but patients see value in reaching into their mailboxes for pharmaceuticals |
The Motley Fool
July 30, 2009
Brian Orelli |
A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money. |
The Motley Fool
October 2, 2011
Shubh Datta |
Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment? |
The Motley Fool
February 23, 2006
Stephen D. Simpson |
Express Scripts Overdue for a Pause This pharmacy benefits manager is posting very good growth and has room for improvement, but what about the stock price? |
The Motley Fool
September 26, 2006
Ryan Fuhrmann |
Jaw-Dropping Pill-Popping at Walgreen How much longer can investors count on Walgreen's stellar numbers? |
The Motley Fool
March 26, 2010
Cathy Applefeld Olson |
Can CVS Caremark Win the Drug Wars? Now that health-care legislation has been signed into law, it's a perfect time to give the country's largest drugstore chain a checkup. |
The Motley Fool
January 5, 2004
Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. |
The Motley Fool
October 28, 2010 |
Our Top Stock Idea Our investing community's latest prime pick -- Medco Health Solutions. |
